On Tuesday, November 10, 2020, the Company, Akebia Therapeutics, Inc., AKBA stock construct a change of 5.71 percent (Gain) in a total of its share price and having its trading value $2.59, which belongs to Healthcare sector and Biotechnology industry. The companys Market capitalization was $382.72M with the total Outstanding Shares of 136.91M.
P/S, P/E, P/B & P /C values of (NASDAQ: AKBA):
Akebia Therapeutics, Inc. institutional ownership is standing at 76.5 percent, while insider ownership is 0.3 percent. As of now, AKBA has a P/S, P/E and, P/B values of 1.24, 0, and 0.96 respectively. Its P/Cash is valued at 1.3.
The stock SMA50 is now at -19.66 percent. In looking, the SMA 200 we see that the stock has seen a -68.64 percent. The Companys net profit margin for the 12 months at -87 percent. Comparatively, the gazes have a Gross margin of 59.3 percent.
Looking into the profitability ratios of AKBA stock, an investor will find its ROE, ROA, ROI standing at -65.8 percent, -34.6 percent and, -59.4 percent, respectively.
A beta factor is used to measure the volatility of the stock. The stock remaining at 7.95 percent volatile for the week and 11.4 percent for the month.
Gross / Operating Margins of AKBA:
It calculates how much out of every dollar of sales a company actually keeps in earnings. Gross Margin is seen at 59.3 percent & Operating Margin seen at -87.4 percent.
Target Price informs the investors, a stock survey at which a trader is willing to buy or sell a stock. At which a trader projects that a buyer will buy a product. The company Akebia Therapeutics, Inc. recorded it at $0.
Historical Performance In The News:
Taking a look at the performance of Akebia Therapeutics, Inc. stock, an investor will come to know that the weekly performance for this stock is valuing at 7.02 percent, resulting in a performance for the month at -21.99 percent.
Therefore, the stated figure displays a quarterly performance of -75.33 percent, bringing six-month performance to -78.07 percent and year to date performance of -59.02 percent. As of now, Akebia Therapeutics, Inc. has a P/S, P/E and, P/B values of 1.24, 0, and 0.96 respectively. Its P/Cash is valued at 1.3.
Earnings per Share Details of Akebia Therapeutics, Inc.:
The EPS of AKBA is strolling at -2.97, measuring its EPS growth this year at 4.5 percent. As a result, the company has an EPS growth of 68.5 percent for the approaching year.
EPS growth is an important number as it gives a suggestion of the future prospects of a company. It is usually expressed as a percentage and is then referred to as the EPS growth rate. Growth in EPS is an important measure of administration performance because it shows how much money the company is making for its investors or shareholders, not only because of changes in profit but also after all the effects of issuance of new shares (this is especially important when the growth comes as a result of acquisition).
Given the importance of identifying companies that will ensure earnings per share at a tall rate, we later obsession to umpire how to identify which companies will achieve high amassing rates. One obvious showing off to identify high earnings per portion count together companies are to locate companies that have demonstrated such build up beyond the p.s. 5 to 10 years.